Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406151 | 1.00 | FGF23 (0.53) | FGF23LMNAALDH1A1TSHRHPGD | |
| SCHEMBL406150 | 1.00 | FGF23 (0.53) | FGF23LMNAALDH1A1TSHRHPGD | |
| Hydrochloric Acid SCHEMBL28411183 | 0.98 | FGF23 (0.52) | FGF23LMNAALDH1A1TSHRHPGD | |
| SCHEMBL7512839 | 0.83 | FGF23 (0.47) | FGF23LMNAALDH1A1TSHRHPGD | |
| SCHEMBL7512835 | 0.83 | FGF23 (0.47) | FGF23LMNAALDH1A1TSHRHPGD | |
| SCHEMBL2161592 | 0.82 | ALOX12 (0.47) | FGF23LMNAALDH1A1TSHRHPGD | |
| SCHEMBL533982 | 0.82 | ALOX12 (0.47) | FGF23LMNAALDH1A1TSHRHPGD | |
| SCHEMBL533983 | 0.82 | ALOX12 (0.47) | FGF23LMNAALDH1A1TSHRHPGD | |
| SCHEMBL6779682 | 0.82 | FGF23 (0.57) | FGF23LMNAALDH1A1TSHRHPGD | |
| SCHEMBL10889088 | 0.81 | ALDH1A1 (0.42) | FGF23LMNAALDH1A1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-8049017-B2 | Preparation of isoxazolin-3-ylacylbenzenes | BASF SE (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110152535-A1 | PREPARATION OF ISOXAZOLIN-3-YLACYLBENZENES | RHEINHEIMER JOACHIM | 2011-06-23 | — | — | US | disclosed |
| US-7906522-B2 | 2-aminoquinazoline derivatives | KYOWA HAKKO KIRIN CO., LTD (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090137583-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-4405357-A | Herbicidal 3-isoxazolidinones and hydroxamic acids | FMC CORPORATION (US) | 1983-09-20 | — | — | US | disclosed |
| US-4206132-A | Lanthanide chelate of a fluorinated ligand | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1980-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152535-A1 | PREPARATION OF ISOXAZOLIN-3-YLACYLBENZENES | CBR3, CYP4X1, UQCRB | FGF23 4713/4885LMNA 2052/4885ALDH1A1 549/4885 |
| US-20090137583-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | SLC7A1, SLC38A7, PRMT7 | FGF23 3304/4885LMNA 2517/4885ALDH1A1 1329/4885 |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | FGF23 4061/4885LMNA 2814/4885ALDH1A1 1374/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | FGF23 4061/4885LMNA 2814/4885ALDH1A1 1374/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | FGF23 4089/4885LMNA 2850/4885ALDH1A1 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.